Calidi Biotherapeutics Stock

www.calidibio.comHealthcare / BioTech & PharmaFounded: 2014

Calidi Biotherapeutics, founded in 2015, is a clinical-stage biotechnology company that strives to pioneer advancements in the field of oncolytic virus-based immunotherapies. The company's mission is to transform the cancer treatment landscape by unlocking the power of the immune system. Calidi Biotherapeutics' novel therapies aim to improve patient survival and quality of life by selectively killing cancer cells while activating immune responses. The company is headquartered in San Diego, California.

Register for Details

For more details on financing and valuation for Calidi Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Calidi Biotherapeutics.

Register Today

Calidi Biotherapeutics investors also invested in these private companies

Jackson Investment Group


Management Team

Allan Camaisa
Co-Founder, Chairman & Chief Executive Officer
Boris Minev
President, Medical and Scientific Affairs & Interim Chief Medical Officer
Tony Kalajian
Chief Accounting Officer & Interim Chief Financial Officer
Stephen Thesing
Chief Business Officer
Wendy Pizarro JD
Chief Legal Officer, Corporate Secretary, Chief Administrative Officer & Chief Diversity Officer
Scott Leftwich
Co-Founder & Vice Chairman

Other companies like Calidi Biotherapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.